Education
About Us
Working with TipRanks
Follow Us
Inmune Bio (INMB)
:INMB
INMB Stock Chart & Stats
$1.92
-$0.22(-3.95%)
At close: 4:00 PM EST
$1.92
-$0.22(-3.95%)
Day’s Range― - ―
52-Week Range$1.38 - $11.64
Previous CloseN/A
Volume114.20K
Average Volume (3M)353.70K
Market Cap
$39.35M
Enterprise Value$28.38M
Total Cash (Recent Filing)$27.73M
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Feb 26, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding26,585,258
10 Day Avg. Volume385,633
30 Day Avg. Volume353,697
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.90
Price to Sales (P/S)6652.75
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue567.55
Enterprise Value/Gross Profit1.29K
Enterprise Value/Ebitda-0.84
Forecast
1Y Price Target
$8.00Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.57
Revenue Forecast (FY)$50.00K
Bulls Say, Bears Say
Bulls Say
Manufacturing AchievementsINmune has successfully completed two commercial pilot-scale manufacturing runs of CORDSTROM at a UK facility, de-risking scale-up and supporting upcoming regulatory filings.
Regulatory ProgressOn the XPro program, the company remains on track to request an End-of-P2 meeting with the FDA, potentially occurring soon, which could provide guidance for a path forward and potentially supporting partnership discussions.
Therapy AdvancementsThe company continues to advance its platform programs, with primary focus on CORDSTROM, its mesenchymal stromal cell (MSC) therapy demonstrating clinical potential in recessive dystrophic epidermolysis bullosa (RDEB).
Bears Say
Competitive Market ChallengesThe therapeutic area of later-line prostate cancer is crowded, and current drugs are very effective, making it difficult to find an ideal treatment slot for INKmune.
Financial LimitationsThe MINDFul trial was limited by financial resources, marking another failure of anti-inflammatory approaches in the treatment of AD.
Stock PerformanceINMB shares moved to a 52-week low back in July on the Alzheimer's trial miss and have yet to recover.
Inmune Bio News
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.38 and its highest was $11.64 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $39.35M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Feb 26, 2026 which is in 92 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on Oct 30, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.078.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.27.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went up 5.78%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (316.67% Upside)
$8.00 (316.67% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.60%
12-Months-Change
Fundamentals
Return on Equity
-155.77%
Trailing 12-Months
Asset Growth
-36.80%
Trailing 12-Months
Company Description
Inmune Bio
Inmune Bio, Inc. (INMB) is a biotechnology company focused on developing innovative therapies to modulate components of the immune system to treat cancer and neurodegenerative diseases. The company operates within the biotechnology and pharmaceutical sectors, leveraging its proprietary platforms to target innate immune cells. Core products in its pipeline include INKmune, which aims to enhance the ability of natural killer cells to attack cancer, and XPro1595, designed to inhibit neuroinflammation linked to Alzheimer's disease.
INMB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment with significant advancements in CORDStrom and INKmune platforms, as well as promising regulatory pathways for XPro. Financial results showed improved operating efficiency, although challenges with XPro trial results and regulatory delays were noted.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$8.00
▲(316.67% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
17.01%
Insiders
4.81% Mutual Funds
1.10% Other Institutional Investors
71.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---